Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: A paradigm of synergistic molecular targeting treatment for ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Karabulut, Bulent ^a   Karaca, Burcak ^a   Varol, Umut ^a   Muslu, Ugur ^a   Cakar, Burcu ^a   Atmaca, Harika ^b   Ksm, Asl ^b   Uzunoglu, Selim ^b   Uslu, Ruchan ^a  

^a EGE UNIVERSITY   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; LYMPHOTOXIN BETA RECEPTOR; RETINOIC ACID; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; MESSENGER RNA; TUMOR MARKER;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; DNA MICROARRAY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DIPHOSPHONATES; DRUG SYNERGISM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77954991297     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-102     Document Type: Article

References (34)

1. Cancer statistics. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387
2. Future directions in the treatment of ovarian cancer. RF Ozols, Semin Oncol 2002 29 1 Suppl 1 32 42 10.1053/sonc.2002.31594 11840418
3. Retinoid-sensitive cells and cell lines. B Amos R Lotan, Methods Enzymol 1990 190 217 225 full-text 2087173
4. The retinoid receptors. DJ Mangelsdorf K Umesono RM Evans, The Retinoids Biology Chemistry and Medicine New York: Raven Pres, Sporn MB, Roberts AB, Goodman DS, 1994 319 349
5. Response of four human ovarian carcinoma cell lines to all trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression. MJ Caliaro C Marmouget S Guichard Ph Mazars A Valette R Moisand R Bugat S Jozan, Int J Cancer 1994 56 743 748 10.1002/ijc.2910560522 8314353
6. Suppression of squamous cell carcinoma growth and differentiation by retinoids. R Lotan, Cancer Res 1994 54 7 Suppl 1987 1990
7. A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. M Bryan ED Pulte KC Toomey L Pliner AC Pavlick T Saunders R Wieder, Invest New Drugs 2010 Jul 2 20596747
8. Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies. KA David NP Mongan C Smith LJ Gudas DM Nanus, Cancer Biol Ther 2010 20200483
9. Randomized Phase II Trial of All-Trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non-Small-Cell Lung Cancer. O Arrieta CH Gonzlez-De la Rosa E Aréchaga-Ocampo G Villanueva-Rodríguez TL Cerán-Lizrraga L Martínez-Barrera ME Vzquez-Manríquez MA Ríos-Trejo MA Alvarez-Avitia N Hernndez-Pedro C Rojas-Marín J De la Garza, J Clin Oncol 2010 Jun 14 20547984
10. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. SA Boorjian MI Milowsky J Kaplan M Albert MV Cobham DM Coll NP Mongan G Shelton D Petrylak LJ Gudas DM Nanus, J Immunother 2007 30 6 655 62 10.1097/CJI.0b013e31805449a8 17667529
11. All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. S Aebi R Kroning B Cenni A Sharma D Fink R Weisman SB Howell RD Christen, Clin Cancer Res 1997 3 2033 2038 9815594
12. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. Y Kucukzeybek MK Gul E Cengiz C Erten B Karaca G Gorumlu H Atmaca S Uzunoglu B Karabulut UA Sanli R Uslu, J Exp Clin Cancer Res 2008 27 37 10.1186/1756-9966- 27-37 18789152
13. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. MJ Caliaro P Vitaux C Lafon I Lochon A Néhmé A Valette P Canal R Bugat S Jozan, Br J Cancer 1997 75 333 340 9020476
14. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. MC Winter I Holen RE Coleman, Cancer Treat Rev 2008 34 453 475 10.1016/j.ctrv.2008.02.004 18423992
15. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. RE Coleman MC Winter D Cameron R Bell D Dodwell MM Keane M Gil D Ritchie JL Passos-Coelho D Wheatley R Burkinshaw SJ Marshall H Thorpe, Br J Cancer 2010 102 7 1099 1105 10.1038/sj.bjc.6605604 20234364
16. Efficacy of the third generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. S Matsumotoa S Kimura H Segawab J Kurodab T Yuasab K Satoa M Nogawab F Tanakaa T Maekawab H Wadaa, Lung Cancer 2005 47 31 39 10.1016/j.lungcan.2004.06.003 15603852
17. Repeated intermittent low-dose therapy with zoledronic acid induces an early, and sustained, and long lasting decrease of vascular endothelial growth factor levels in cancer patients. D Santini B Vincenzi S Galluzzo F Battistoni L Rocci O Venditti G Schiavon S Angeletti F Uzzalli M Caraglia G Dicuonzo G Tonini, Clin Cancer Res 2007 13 4482 4486 10.1158/1078-0432.CCR-07-0551 17671133
18. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomized, phase 2 trial. R Aft M Naughton K Trinkaus M Watson L Ylagan M Chavez-MacGregor J Zhai S Kuo W Shannon K Diemer V Herrmann J Dietz A Ali M Ellis P Weiss T Eberlein C Ma PM Fracasso I Zoberi M Taylor W Gillanders T Pluard J Mortimer K Weilbaecher, Lancet Oncol 2010 11 5 421 428 10.1016/S1470-2045(10)70054-1 20362507
19. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. M Gnant B Mlineritsch GL Luschin-Ebengreuth F Kainberger H Kassmann JC Piswanger-Sölkner M Seifert F Ploner C Menzel P Dubsky F Fitzal V Bjelic-Radisic G Steger R Greil C Marth E Kubista H Samonigg P Wohlmuth M Mittlböck R Jakesz, Lancet Oncol 2008 9 840 849 10.1016/S1470-2045(08) 70204-3 18718815
20. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. TC Hamilton RC Young WM McKoy KR Grotzinger JA Green EW Chu J Whang-Peng AM Rogan WR Green RF Ozols, Cancer Res 1983 43 5379 5388 6604576
21. Regulation of growth factors in hormone- and drug resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. C Erten B Karaca Y Kucukzeybek G Gorumlu E Cengiz MK Gul H Atmaca S Uzunoglu B Karabulut UA Sanli R Uslu, BJU Int 2009 104 107 114 10.1111/j.1464-410X.2009.08340.x 19191785
22. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs on enzyme inhibitors. TC Chou P Talalay, Adv Enzyme Regul 1984 22 27 55 10.1016/0065-2571(84)90007-4 6382953
23. Ligand based Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL). A Ashkenazi P Holland Eckhardt, J Clin Oncol 2008 26 3621 3630 10.1200/JCO.2007.15.7198 18640940
24. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. H Hsu HB Shu MG Pan DV Goeddel, Cell 1996 84 299 306 10.1016/S0092-8674(00)80984-8 8565075
25. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. M Muzio AM Chinnaiyan FC Kischkel K O'Rourke A Shevchenko J Ni C Scaffidi JD Bretz M Zhang R Gentz M Mann PH Krammer ME Peter VM Dixit, Cell 1996 85 817 827 10.1016/S0092-8674(00) 81266-0 8681377
26. TNF- mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. DP Chopra RE Menard J Januszewski RR Mattingly, Cancer Lett 2004 203 145 154 10.1016/j.canlet.2003.09.016 14732222
27. All-trans-retinoic acid up regulates TNF receptors and potentiates TNF-induced activation of nuclear factors-B, activated protein-1 and apoptosis in human lung cancer cells. SK Mana BB Aggarwal, Oncogene 2000 19 2110 2119 10.1038/sj.onc.1203547 10815802
28. Apoptosis signaling. A Strasser L O'Connor VM Dixit, Annu Rev Biochem 2000 69 217 245 10.1146/annurev.biochem.69.1.217 10966458
29. Life-or-death decisions by the Bcl-2 protein family. JM Adams S Cory, Trends Biochem Sci 2001 26 61 66 10.1016/S0968-0004(00)01740-0 11165519
30. Bis, a Bcl-2- binding protein that synergizes with Bcl-2 in preventing cell death. JH Lee T Takahashi N Yasuhara J Inazawa S Kamada Y Tsujimoto, Oncogene 1999 18 6183 6190 10.1038/sj.onc.1203043 10597216
31. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. KJ Aichberger M Mayerhofer KV Gleixner MT Krauth A Gruze WF Pickl V Wacheck E Selzer L Müllauer H Agis C Sillaber P Valent, Blood 2007 109 3031 3041 17110460
32. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. MA Degli-Esposti T Davis-Smith WS Din PJ Smolak RG Goodwin CA Smith, J Immunol 1997 158 1756 1762 9029113
33. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. M Lukashev D LePage C Wilson V Bailly E Garber A Lukashin A Ngam-ek W Zeng N Allaire S Perrin X Xu K Szeliga K Wortham R Kelly C Bottiglio J Ding L Griffith G Heaney E Silverio W Yang M Jarpe S Fawell M Reff A Carmillo K Miatkowski J Amatucci T Crowell H Prentice W Meier SM Violette F Mackay D Yang R Hoffman JL Browning, Cancer Res 2006 66 9617 9624 10.1158/0008-5472.CAN-06-0217 17018619
34. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. MC Winter I Holen RE Coleman, Cancer Treat Rev 2008 34 453 475 10.1016/j.ctrv.2008.02.004 18423992